OSAKA, Japan & CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, Protagonist Therapeutics and Takeda Pharmaceutical Company Limited (NYSE ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.

Takeda has partnered with patient data firm Seqster in a drive to improve care through better access and understanding of patient-level data. The partnership follows Takeda's investment in the US ...

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹ ...

Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout By Nick Paul Taylor Jun 27, 2025 9:00am Turnstone Biologics Xoma mergers and acquisitions Oncology ...

TAK Company Profile Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.

Takeda Ireland has received the award for overall excellence in life sciences at the Life Sciences Industry Awards 2025, the annual event that celebrates the most innovative individuals and ...

View the latest Takeda Pharmaceutical Co. Ltd. ADR (TAK) stock price, news, historical charts, analyst ratings and financial information from WSJ.